UBS AM’s CRISPR Therapeutics CRSP Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.49M Buy
157,396
+8,495
+6% +$448K ﹤0.01% 1364
2025
Q4
$7.81M Buy
+148,901
New +$8.92M ﹤0.01% 1239
2025
Q3
Sell
-964,690
Closed -$46.9M 2357
2025
Q2
$46.9M Sell
964,690
-988,061
-51% -$38.2M 0.01% 720
2025
Q1
$66.5M Buy
1,952,751
+1,262,560
+183% +$53.5M 0.02% 626
2024
Q4
$27.2M Buy
690,191
+13,865
+2% +$655K 0.01% 839
2024
Q3
$31.8M Sell
676,326
-17,632
-3% -$895K 0.01% 791
2024
Q2
$37.5M Buy
693,958
+583,493
+528% +$33.8M 0.01% 682
2024
Q1
$7.53M Buy
110,465
+14,515
+15% +$1.04M ﹤0.01% 1100
2023
Q4
$6.01M Buy
95,950
+2,825
+3% +$156K ﹤0.01% 1174
2023
Q3
$4.23M Buy
93,125
+10,839
+13% +$560K ﹤0.01% 1287
2023
Q2
$3.72M Hold
82,286
﹤0.01% 1366
2023
Q1
$3.72M Buy
82,286
+6,380
+8% +$310K ﹤0.01% 1366
2022
Q4
$3.09M Buy
75,906
+120
+0.2% +$6.37K ﹤0.01% 1346
2022
Q3
$4.95M Sell
75,786
-57,368
-43% -$4.16M ﹤0.01% 1206
2022
Q2
$8.09M Buy
133,154
+13,827
+12% +$813K ﹤0.01% 1045
2022
Q1
$7.49M Sell
119,327
-206
-0.2% -$12.9K ﹤0.01% 1182
2021
Q4
$9.06M Buy
119,533
+5,113
+4% +$447K ﹤0.01% 1161
2021
Q3
$12.8M Sell
114,420
-2,793
-2% -$351K 0.01% 997
2021
Q2
$19M Sell
117,213
-23,841
-17% -$2.9M 0.01% 898
2021
Q1
$17.2M Buy
141,054
+34,308
+32% +$5.18M 0.01% 901
2020
Q4
$16.3M Sell
106,746
-13,846
-11% -$1.64M 0.01% 899
2020
Q3
$10.1M Sell
120,592
-18,438
-13% -$1.64M 0.01% 939
2020
Q2
$10.2M Buy
139,030
+8,702
+7% +$509K 0.01% 901
2020
Q1
$5.53M Buy
+130,328
New +$6.73M ﹤0.01% 1021

Other funds holding CRSP